Medicis rated 'Strong Sell' on weak dermatology sales

Analysts give US-based Medicis Pharmaceutical a "Strong Sell" rating after dermatology sales disappoint

Matrix Research analysts have given US-based Medicis Pharmaceutical a "Strong Sell" rating.

Analysts say that the company's dermatology sales had risen only four per cent over the eight-quarter period ended June 2007. With a 40 per cent rise in Medicis' capital over the period, the company's return on capital has declined significantly.

In August 2007, Swedish biotechnology company Q-Med said it was eyeing a merger with Medicis.

Q-Med's CEO, Bengt Agerup, who owns 47.5 per cent of the firm, said that a union with Medicis made "industrial sense". The company had partnered with Medicis on the marketing of the Swedish firm's cosmetic filler Restylane.

No concrete merger talks were ongoing at the time, but if the valuations of the company changed, talks might be initiated, added Agerup.

17th September 2007

PME Digital Edition

COVID-19 Updates and Daily News

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?: The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer: To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID-19 – a catalyst for technology adoption in clinical trials: As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...